About Riddhima Chakraborty
Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries.
Recent Articles By Riddhima Chakraborty
1 Tech Stock to Avoid with a Ton of Headwinds Still Ahead
Palantir Technologies (PLTR) has lost more than 50% year-to-date and is trading near its 52-week low. Given its weak fundamentals and the broader macro headwinds, the tech stock could witness a further downtrend. Therefore, it might be best to avoid PLTR now. Keep reading…
2 Momentum Stocks You Can Buy for Under $50 Now
The bullish sentiment surrounding the short-term outlook of the overall market has improved to a nine-week high. Therefore, investors could consider buying under-$50 stocks APA (APA) and Ovintiv (OVV), which have gained momentum and are well-positioned to continue the same. Read on…
1 Stock to Buy in Q4 if You Haven't Already
Health service provider CVS Health (CVS) is aiming for an $8 billion acquisition of Signify Health (SGFY). The company’s strength is reflected in its latest quarterly financials. Hence, the stock might be a solid buy in the fourth quarter. Let's find out…
Get in on This Railroad Stock Before It Leaves the Station
Railroad company CSX Corporation’s (CSX) financials surpassed analyst estimates in the third quarter, defying market uncertainties. Moreover, Wall Street analysts expect the stock to grow more than 10% in the near term. Hence, investors should not delay investing in this railroad stock. Read on…
The Worst Biotech Stocks Investors Could Buy This Fall
Timber Pharmaceuticals (TMBR) recently received an NYSE warning for not meeting the minimum trading price requirement for quite some time. The stock has lost 84% year-to-date. Given the company’s weak fundamentals, the stock could be a poor choice for investors enticed by its negligible price. Let’s discuss…
This Health Care Stock Is a No-Brainer Buy for Fall
Merck & Co.’s (MRK) third-quarter financials surpassed Wall Street’s expectations. The stock is trading near its 52-week high of $101.50, and its momentum is expected to continue, considering its strong fundamentals. Given the company’s solid growth, reliable dividend payments, and the resilience of its sector against the expected economic slowdown, this stock might be a no-brainer pick now. Read on…
1 Stock That’s Not a Bargain Despite Being Down 53% in 2022
Popular chip maker NVIDIA (NVDA) is currently struggling to keep up its sales amid government restrictions and weakening demand. Although the stock has lost 53% in 2022, it’s still not a bargain. Let’s discuss this in detail…
1 Stock You Shouldn’t Buy Even Though Warren Buffett Did
Floor & Decor (FND) has secured a place in veteran investor Warren Buffet’s portfolio. However, this does not make it a reliable investment now. Several analysts have lowered their price target for FND recently. Moreover, the stock lost more than 40% in 2022. Let’s discuss this in detail…
Buy and Hold This 1 Chip Stock for Big-Time Gains in Q4
Broadcom (AVGO) shares have been on a downtrend this year amid the broader tech selloff. However, Wall Street analysts are bullish on its near-term prospects, given its solid fundamentals. They see a more than 45% upside potential in the stock. Therefore, investors might consider buying and holding AVGO for big-time gains. Keep reading…